PURPOSE: To obtain a pharmaceutical preparation containing arecolone and isoaecolone and used for treatment of Alzheimer's disease, the other central nervous system-related diseases, pain, gastroenteric diseases and diabetes mellitus. CONSTITUTION: This pharmaceutical preparation comprises a compound of formula I or formula II (R is a 2-6C alkyl, a 2-6C alkenyl, a 2-6C alkinyl, a 2-6C alkoxyalkyl, a 2-6C alkylthioalkyl, a 2-6C alkylaminoalkyl, a 3-6C cycloalkyl or a 1-6C alkyl substituted with 3-6C cycloalkyl or a 1-6C polyfluoroalkyl; R1 is H or 1 or 2 1-3C alkyl) or its physiologically active acid addition salt, e.g. 1-(1,2,5,6-tetrahydro-1-methyl-3-pydinyl)-1-propanone hydrochloride as an active ingredient. The compound has cholinergic nicotinic activity and has selective affinity for nicotinic receptor.
展开▼
机译:目的:获得含有槟榔酮和异aecolone的药物制剂,用于治疗阿尔茨海默氏病,其他与中枢神经系统有关的疾病,疼痛,胃肠道疾病和糖尿病。组成:该药物制剂包含式I或式II的化合物(R为2-6C烷基,2-6C烯基,2-6C炔基,2-6C烷氧基烷基,2-6C烷硫基烷基,2- 6C烷基氨基烷基,被3-6C环烷基或1-6C多氟烷基取代的3-6C环烷基或1-6C烷基; R 1是H或1或2 1-3C烷基)或其生理活性酸加成盐,例如以1-(1,2,5,6-四氢-1-甲基-3-吡啶基)-1-丙酮盐酸盐为有效成分。该化合物具有胆碱能的烟碱活性,并且对烟碱受体具有选择性的亲和力。
展开▼